Fighting the uphill battle to cure type 1 diabetes

Three complementary approaches for type 1 diabetes. Immunotherapy targets the pathogenic immune cells or inflammatory cytokines to revert type 1 diabetes. An artificial pancreas delivers insulin automatically using continuous glucose monitoring, a controlling algorithm, and an insulin pump. Beta cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eun Young, Yoon, Kun‐Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409888/
https://www.ncbi.nlm.nih.gov/pubmed/34110690
http://dx.doi.org/10.1111/jdi.13613
_version_ 1783747058441650176
author Lee, Eun Young
Yoon, Kun‐Ho
author_facet Lee, Eun Young
Yoon, Kun‐Ho
author_sort Lee, Eun Young
collection PubMed
description Three complementary approaches for type 1 diabetes. Immunotherapy targets the pathogenic immune cells or inflammatory cytokines to revert type 1 diabetes. An artificial pancreas delivers insulin automatically using continuous glucose monitoring, a controlling algorithm, and an insulin pump. Beta cell replacement therapy varies depending on the cell sources: allogeneic, or xenogeneic islet; beta‐like cells derived from ESCs or iPSCs.[Image: see text]
format Online
Article
Text
id pubmed-8409888
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84098882021-09-03 Fighting the uphill battle to cure type 1 diabetes Lee, Eun Young Yoon, Kun‐Ho J Diabetes Investig Commentaries Three complementary approaches for type 1 diabetes. Immunotherapy targets the pathogenic immune cells or inflammatory cytokines to revert type 1 diabetes. An artificial pancreas delivers insulin automatically using continuous glucose monitoring, a controlling algorithm, and an insulin pump. Beta cell replacement therapy varies depending on the cell sources: allogeneic, or xenogeneic islet; beta‐like cells derived from ESCs or iPSCs.[Image: see text] John Wiley and Sons Inc. 2021-07-22 2021-09 /pmc/articles/PMC8409888/ /pubmed/34110690 http://dx.doi.org/10.1111/jdi.13613 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentaries
Lee, Eun Young
Yoon, Kun‐Ho
Fighting the uphill battle to cure type 1 diabetes
title Fighting the uphill battle to cure type 1 diabetes
title_full Fighting the uphill battle to cure type 1 diabetes
title_fullStr Fighting the uphill battle to cure type 1 diabetes
title_full_unstemmed Fighting the uphill battle to cure type 1 diabetes
title_short Fighting the uphill battle to cure type 1 diabetes
title_sort fighting the uphill battle to cure type 1 diabetes
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409888/
https://www.ncbi.nlm.nih.gov/pubmed/34110690
http://dx.doi.org/10.1111/jdi.13613
work_keys_str_mv AT leeeunyoung fightingtheuphillbattletocuretype1diabetes
AT yoonkunho fightingtheuphillbattletocuretype1diabetes

Ejemplares similares